Why Your Gout Keeps Coming Back
If you’ve had more than two gout flares in a year, you’re dealing with recurrent gout, and that changes the treatment conversation entirely. Recurrent gout isn’t just bad luck. It usually means uric acid crystals have built up in your joints and your current treatment isn’t keeping your serum urate level below 6 mg/dL.
The American College of Rheumatology (ACR) 2020 guideline recommends urate-lowering therapy (ULT) for anyone with two or more gout flares per year, tophi, or evidence of urate crystal deposition on imaging. The question isn’t whether to treat, it’s how.
Traditional Urate-Lowering Medications
Allopurinol (Zyloprim)
Allopurinol has been the first-line ULT since the 1960s. It works by blocking xanthine oxidase, the enzyme that produces uric acid. The ACR guideline recommends allopurinol as the preferred initial ULT for most patients.
Key facts:
- Starting dose: 100 mg daily (lower in patients with chronic kidney disease)
- Target: Titrate up to reach serum urate below 6 mg/dL
- Maximum dose: 800 mg daily
- Cost: Very affordable (most generic versions under $10/month)
The CARES trial (2018), published in The New England Journal of Medicine, found no significant difference in cardiovascular outcomes between allopurinol and febuxostat in patients with gout and cardiovascular disease. This was reassuring for allopurinol’s safety profile.
Febuxostat (Uloric)
Febuxostat is a newer xanthine oxidase inhibitor that the Food and Drug Administration (FDA) approved in 2009. It’s often used when allopurinol fails to reach target urate levels or causes adverse reactions.
Key facts:
- Available doses: 40 mg and 80 mg daily
- More potent than allopurinol at standard doses
- Does not require renal dose adjustment for mild-to-moderate chronic kidney disease (CKD)
- Cost: Significantly more expensive than allopurinol
The FAST trial (2020), published in The Lancet, found that febuxostat was non-inferior to allopurinol for cardiovascular outcomes and actually showed lower rates of all-cause mortality and cardiovascular death. Based on this, the FDA removed the boxed warning for febuxostat cardiovascular risk in 2024.
Probenecid
Probenecid works differently, it increases uric acid excretion through the kidneys (uricosuric agent). The ACR recommends it as an alternative for patients who cannot tolerate xanthine oxidase inhibitors, provided kidney function is adequate.
Limitations:
- Less effective in patients with estimated glomerular filtration rate (eGFR) below 50 mL/min
- Requires adequate hydration
- Risk of kidney stones
- Multiple daily dosing
Modern Biologic Approaches
Pegloticase (Krystexxa)
Pegloticase is the only FDA-approved biologic for gout. It’s a PEGylated uricase enzyme that converts uric acid into allantoin, a substance the body can easily eliminate. It’s reserved for the most severe cases: patients with uncontrolled gout who have failed conventional ULT.
How it works: Humans lost the uricase gene during evolution, so we can’t break down uric acid the way most mammals do. Pegloticase essentially gives that enzyme back.
Key facts:
- Administration: intravenous (IV) infusion every two weeks
- Response rate: Approximately 42% of patients achieve serum urate below 6 mg/dL at 6 months
- Anti-drug antibodies develop in many patients, leading to loss of efficacy
- Infusion reactions possible, pre-medication required
- Cost: Approximately $500,000+ per year before insurance
Pegloticase + Methotrexate: A Game Changer
A landmark 2022 study published in JAMA showed that combining pegloticase with low-dose methotrexate (15 mg/week) dramatically improved response rates. The MIRROR randomized clinical trial found:
- 60% response rate with pegloticase + methotrexate vs. 38.5% with pegloticase + placebo
- Significantly fewer infusion reactions
- Lower rates of anti-drug antibody formation
This combination is now considered the standard of care for patients starting pegloticase therapy.
Head-to-Head Comparison
| Factor | Allopurinol | Febuxostat | Pegloticase |
|---|---|---|---|
| Mechanism | Xanthine oxidase inhibitor | Xanthine oxidase inhibitor | Recombinant uricase |
| Route | Oral | Oral | IV infusion |
| Starting dose | 100 mg/day | 40 mg/day | 8 mg q2 weeks |
| Urate-lowering potency | Moderate | Moderate-High | Very High |
| CKD considerations | Dose adjust | No adjust (mild-moderate) | Safe in CKD |
| Monthly cost (US) | $5-15 | $200-400 | $40,000+ |
| ACR recommendation | First-line | Alternative first-line | Refractory gout only |
When Traditional Meds Aren’t Enough
Most people with gout, roughly 70-80%, can achieve target urate levels with allopurinol or febuxostat when properly titrated. The problem is undertreatment. Studies show that fewer than half of people with gout on allopurinol ever reach the target serum urate of 6 mg/dL, often because doses are never increased beyond 300 mg.
The ACR recommends “treat-to-target”, start low, increase every 2-5 weeks, and keep going until serum urate is below 6 mg/dL (below 5 mg/dL if tophi are present). This means many patients need 300-600 mg of allopurinol daily, and some need even more.
If maximum-dose allopurinol or febuxostat doesn’t get you to target, the next step is combination therapy: adding probenecid or a lesinurad-based option to a xanthine oxidase inhibitor.
Only when all conventional options fail, and gout remains uncontrolled with frequent flares, tophi, or joint damage, should pegloticase be considered.
Flare Prevention During ULT
One of the most frustrating aspects of starting urate-lowering therapy is that it can temporarily increase gout flares. As uric acid crystals dissolve, they can trigger inflammation. The ACR strongly recommends:
- Colchicine 0.6 mg once or twice daily for at least 3-6 months when starting ULT
- Alternatively, low-dose nonsteroidal anti-inflammatory drugs (NSAIDs) (e.g., naproxen 250 mg twice daily) for flare prevention
- Do not stop ULT during flares, continue urate-lowering while treating the flare
Making the Right Choice With Your Doctor
There is no one-size-fits-all answer. The best treatment depends on your kidney function, cardiovascular health, flare frequency, tophi burden, and insurance coverage. But here are some principles:
- Start with allopurinol unless you have a specific reason not to (e.g., HLA-B*58:01 allele, which increases risk of severe skin reactions, particularly in people of Han Chinese, Korean, Thai, or African American descent)
- Treat to target — your doctor should check serum urate every 2-5 weeks during titration
- If allopurinol fails, switch to febuxostat or add a uricosuric
- Reserve pegloticase for truly refractory gout after failing conventional ULT
- Be sure to use flare prophylaxis when starting or adjusting ULT
Practical Tips for Managing Gout Through Diet
Beyond knowing which foods to avoid, the practical side of a gout-friendly diet deserves attention. Meal planning becomes easier when you focus on what you can eat rather than what you cannot. Most vegetables, whole grains, low-fat dairy products, eggs, and plant-based proteins like tofu are safe choices that do not raise uric acid levels.
One strategy that works well for many people with gout is the “plate method”: fill half your plate with vegetables, one quarter with lean protein (chicken, fish in moderation, or plant-based options), and one quarter with whole grains. This naturally limits purine-heavy foods without requiring complex calorie counting or strict meal plans.
Hydration deserves special emphasis. Water helps your kidneys process and reduce uric acid more efficiently. Some patients find that adding lemon to their water provides additional benefit — citric acid may help alkalinize urine, promoting uric acid excretion. While the evidence for lemon water is not as strong as for prescription medications, it is a low-risk strategy worth trying alongside other dietary changes.
Cooking methods also matter more than most people realize. Boiling purine-rich meats and discarding the cooking liquid can reduce their purine content by up to 50%. This means that a boiled chicken breast is a safer choice than the same chicken cooked in its own juices or grilled with the skin on.
Frequently Asked Questions
What foods trigger gout the most?
Organ meats (liver, kidney), certain seafood (anchovies, sardines, shellfish), and high-fructose foods are the biggest dietary triggers. Red meat and beer also raise uric acid significantly. Not everyone reacts the same way, so tracking your personal triggers with a food diary can help you identify your specific problem foods.
Can I ever eat steak or seafood again?
Yes, in moderation. A small portion of lean red meat (3–4 oz) once or twice a week is usually fine for most people with gout. The key is balancing purine-rich foods with plenty of water, low-fat dairy, and vegetables. Talk to your doctor about what portions work for your uric acid levels.
Do vegetables high in purines cause gout attacks?
No. Research consistently shows that purines from plant sources — even high-purine vegetables like spinach, mushrooms, and lentils — do not increase gout risk. Only animal-derived purines significantly raise uric acid levels. This is one of the most common misunderstandings about gout diets.
How much water should I drink to prevent gout?
Most rheumatologists recommend at least 8 glasses (64 oz) of water daily. Staying well-hydrated helps your kidneys flush out excess uric acid. During a flare, increasing fluid intake can help speed recovery. Coffee and low-fat milk also have mild uric-acid-lowering effects.
Related: Allopurinol vs Febuxostat | Colchicine Guide | NSAIDs Comparison
Compare biologics with traditional options: allopurinol vs febuxostat.
For flare management, see our colchicine guide.
References
- FitzGerald JD, et al. 2020 American College of Rheumatology Guideline for the Management of Gout. Arthritis Rheumatol. 2020;72(6):879-895. PubMed
- White WB, et al. Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout (CARES). N Engl J Med. 2018;378(13):1200-1210. PubMed
- Mackenzie IS, et al. Long-term Cardiovascular Safety of Febuxostat Compared with Allopurinol (FAST). Lancet. 2020;396(10264):1745-1757. PubMed
- Sundy JS, et al. Efficacy and Tolerability of Pegloticase for the Treatment of Chronic Gout Refractory to Conventional Treatment. JAMA. 2011;306(7):711-720. PubMed
- Botson JK, et al. Pegloticase Response Improvement with Methotrexate (MIRROR). JAMA. 2022;328(13):1308-1317. PubMed
- US Food and Drug Administration. Uloric (febuxostat): Drug Safety Communication. FDA, 2024. FDA
Reviewed by the GoutSavvy Editorial Team